Early vascular healing after implantation of the polymer-free biolimus-eluting stent or the ultrathin strut biodegradable polymer sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction.
Journal
Coronary artery disease
ISSN: 1473-5830
Titre abrégé: Coron Artery Dis
Pays: England
ID NLM: 9011445
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
6
1
2022
medline:
8
4
2022
entrez:
5
1
2022
Statut:
ppublish
Résumé
To evaluate the difference in early vascular healing between the ultrathin-strut biodegradable-polymer sirolimus-eluting Orsiro stent (O-SES) and the polymer-free biolimus-A9-eluting BioFreedom stent (BF-BES), assessed with optical coherence tomography (OCT) after primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarctions (STEMIs). Eighty patients with STEMI who underwent primary PCI were randomly allocated 1:1 to treatment with BF-BES or O-SES. OCT was acquired after PCI and at 1-month follow-up. The primary endpoint was 1-month OCT-assessed vascular healing index based on the presence of uncovered and malapposed stent struts and intraluminal filling defects where low vascular healing index indicated favorable vascular healing. At 1-month, the vascular healing index was similar in O-SES 11.5 [interquartile range (IQR) 9.5-17.5], compared to BF-BES 11.5 (IQR 7.1-12.5; P = 0.14). Percentage of uncovered struts [O-SES 31.5% (IQR 20.7-41.9), P = 0.43] vs. BF-BES 27.8% (IQR 19.4-41.9; P = 0.44), and median volume of neointimal hyperplasia [O-SES 4.9 mm3 (IQR 1.4-13.1) vs. BF-BES 7.1 mm3 (IQR 2.8-17.0), P = 0.18] did not differ significantly between the two stent groups. Complete coverage was not observed in any of the stents. The percentages of stents with malapposition did not differ significantly (O-SES 87.1% vs. BF-BES 71.4%, P = 0.14) whereas percentage of malapposed struts [O-SES 3.5% (IQR 0.8-5.5) vs. BF-BES 0.8% (IQR 0.0-1.8), P = 0.003] was lower in the BF-BES group. In patients with STEMI, the drug-coated BF-BES and the thin strut O-SES had similar vascular healing index at 1-month. However, the thin O-SES struts were more often malapposed.
Identifiants
pubmed: 34985003
doi: 10.1097/MCA.0000000000001113
pii: 00019501-202205000-00006
doi:
Substances chimiques
Polymers
0
Sirolimus
W36ZG6FT64
Banques de données
ClinicalTrials.gov
['NCT02915107']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
196-205Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, Bottcher M, et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 2007; 50:463–470.
Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 2013; 6:1267–1274.
Ullrich H, Münzel T, Gori T. Coronary stent thrombosis- predictors and prevention. Dtsch Arztebl Int 2020; 117:320–326.
Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115:2435–2441.
Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O, et al.; Intracoronary Stenting and Angiographic Restenosis Investigators–Test Efficacy of Rapamycin-eluting Stents with Different Polymer Coating Strategies (ISAR-TEST-3). Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008; 29:1975–1982.
Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, et al.; DELIVER Clinical Trial Investigators. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004; 109:1948–1954.
Costa RA, Abizaid A, Mehran R, Schofer J, Schuler GC, Hauptmann KE, et al.; BioFreedom FIM Clinical Trial Investigators. Polymer-free biolimus A9-coated stents in the treatment of de novo coronary lesions: 4- and 12-month angiographic follow-up and final 5-year clinical outcomes of the prospective, multicenter biofreedom FIM clinical trial. JACC Cardiovasc Interv 2016; 9:51–64.
Lipiecki J, Brunel P, Morice MC, Roguelov C, Walsh SJ, Richardt G, et al. Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial. EuroIntervention 2018; 14:e418–e425.
Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, et al.; ONYX ONE Investigators. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med 2020; 382:1208–1218.
Jensen Lisette Okkels, Maeng M, Raungaard B, Kahlert J, Ellert J, Jakobsen L, et al.; Sort Out IX Study Group. Randomized comparison of the polymer-free biolimus-coated biofreedom stent with the ultrathin strut biodegradable polymer sirolimus-eluting orsiro stent in an all-comers population treated with percutaneous coronary intervention: the SORT OUT IX Trial. Circulation 2020; 141:2052–2063.
Prati F, Guagliumi G, Mintz GS, Costa M, Regar E, Akasaka T, et al.; Expert’s OCT Review Document. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J 2012; 33:2513–2520.
Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37:1478–1492.
Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al.; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39:213–260.
Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C, et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv 2010; 3:174–183.
Andreasen LN, Holm NR, Balleby IR, Krusell LR, Maeng M, Jakobsen L, et al. Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study. Eur Heart J Cardiovasc Imaging 2018; 19:329–338.
Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al.; International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT). Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 2012; 59:1058–1072.
Radu MD, Räber L, Kalesan B, Muramatsu T, Kelbæk H, Heo J, et al. Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study. Eur Heart J 2014; 35:795–807.
Antonsen L, Thayssen P, Maehara A, Hansen HS, Junker A, Veien KT, et al. Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Nobori Stent Implantation in Patients With Non-ST-Segment-Elevation Myocardial Infarction (OCTACS) Trial: Difference in Strut Coverage and Dynamic Malapposition Patterns at 6 Months. Circ Cardiovasc Interv 2015; 8:e002446.
Räber L, Kelbæk H, Taniwaki M, Ostojic M, Heg D, Baumbach A, et al.; COMFORTABLE AMI Trial Investigators. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. Circ Cardiovasc Interv 2014; 7:355–364.
Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011; 123:1400–1409.
Otsuka F, Nakano M, Ladich E, Kolodgie FD, Virmani R. Pathologic etiologies of late and very late stent thrombosis following first-generation drug-eluting stent placement. Thrombosis 2012; 2012:608593.
Balleby IR, Andreasen LN, Hebsgaard L, Barkholt TO, Terkelsen C, Jensen L, et al. Early healing after treatment of coronary lesions by everolimus or biolimus eluting bioresorbable polymer stents: The sort-out viii optical coherence tomography study. J Am Coll Cardiol. 2016; 67:436
Gomez-Lara J, Ortega-Paz L, Brugaletta S, Cuesta J, Romaní S, Serra A, et al.; Collaborators. Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial. EuroIntervention 2020; 16:e913–e921.
García-Touchard A, Gonzalo N, Goicolea J, Gomez-Lara J, Martín-Yuste V, Peral V, et al. Early coronary healing in st segment elevation myocardial infarction: Sirolimus-eluting stents vs. drug-coated balloons after bare-metal stents. The pebsi-2 optical coherence tomography randomized study. Coronary artery disease 2021; 32:673–680.
Lee SWL, Tam FCC, Chan KKW, Lam SCC, Kong SL, Shea CP, et al. Establishment of healing profile and neointimal transformation in the new polymer-free biolimus A9-coated coronary stent by longitudinal sequential optical coherence tomography assessments: the EGO-BIOFREEDOM study. EuroIntervention 2018; 14:780–788.
Giblett JP, Brown AJ, Keevil H, Jaworski C, Hoole SP, West NE. Implantation of bioresorbable vascular scaffolds following acute coronary syndrome is associated with reduced early neointimal growth and strut coverage. EuroIntervention 2016; 12:724–733.
Kim JS, Fan C, Choi D, Jang IK, Lee JM, Kim TH, et al. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int J Cardiol 2011; 146:341–346.
Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 2008; 118:1138–1145.
Amabile N, Trouillet C, Meneveau N, Tissot CM, Belle L, Combaret N, et al. Mechanical abnormalities associated with first- and second-generation drug-eluting stent thrombosis analyzed by optical coherence tomography in the national PESTO French registry. Int J Cardiol 2017; 227:161–165.
Nakatani S, Onuma Y, Ishibashi Y, Karanasos A, Regar E, Garcia-Garcia HM, et al. Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study. EuroIntervention 2015; 11:885–894.
Tada T, Kadota K, Hosogi S, Kubo S, Ozaki M, Yoshino M, et al. Optical coherence tomography findings in lesions after sirolimus-eluting stent implantation with peri-stent contrast staining. Circ Cardiovasc Interv 2012; 5:649–656.
Alfonso F, Pérez-Vizcayno MJ, Ruiz M, Suárez A, Cazares M, Hernández R, et al. Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings. J Am Coll Cardiol 2009; 53:2053–2060.
Hansen KN, Antonsen L, Maehara A, Mæng M, Ellert J, Ahlehoff O, et al. Influence of plaque characteristics on early vascular healing in patients with ST-elevation myocardial infarction. Cardiovasc Revasc Med 2021; 30:50–58.
Karjalainen PP, Varho V, Nammas W, Mikkelsson J, Pietilä M, Ylitalo A, et al. Early neointimal coverage and vasodilator response following biodegradable polymer sirolimus-eluting vs. durable polymer zotarolimus-eluting stents in patients with acute coronary syndrome –HATTRICK-OCT trial. Circ J 2015; 79:360–367.